Figure 4.
Figure 4. Peak number of immunosuppressive agents used across time for the treatment of GVHD after nonmyeloablative or myeloablative conditioning. Shown are the proportions of patients treated with 0, 1, 2, 3, or 4 agents at different time points during 12 months after transplantation. Values at 1 to 6 months after transplantation represent peak numbers of immunosuppressive agents given during the respective month. Values at 9 and 12 months represent peak numbers of immunosuppressive agents given between 7 to 9 months and 10 to 12 months after transplantation. Upper panel, nonmyeloablative transplantation; lower panel, myeloablative transplantation.

Peak number of immunosuppressive agents used across time for the treatment of GVHD after nonmyeloablative or myeloablative conditioning. Shown are the proportions of patients treated with 0, 1, 2, 3, or 4 agents at different time points during 12 months after transplantation. Values at 1 to 6 months after transplantation represent peak numbers of immunosuppressive agents given during the respective month. Values at 9 and 12 months represent peak numbers of immunosuppressive agents given between 7 to 9 months and 10 to 12 months after transplantation. Upper panel, nonmyeloablative transplantation; lower panel, myeloablative transplantation.

Close Modal

or Create an Account

Close Modal
Close Modal